A Randomized, 24-week, Open-label, 2-arm Parallel-group, Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine on Top of Metformin in Type 2 Diabetic Patients

Primary Objective:

- The purpose of this study was to compare insulin glargine/ lixisenatide fixed ratio
combination (FRC) versus insulin glargine on glycemic control over 24 weeks, as
evaluated by glycosylated hemoglobin (HbA1c) reduction in type 2 diabetic participants
treated with metformin.

Secondary Objectives:

- To compare insulin glargine/lixisenatide FRC versus insulin glargine over 24 weeks on:

- Glycemic control in relation to a meal as evaluated by post-prandial plasma glucose
and glucose excursions during a standardized meal test;

- Percentage of participants reaching HbA1c <7% or ≤6.5%;

- 7-point Self-Monitored Plasma Glucose (SMPG) profile;

- Body weight;

- Insulin glargine dose

- Fasting Plasma Glucose (FPG);

- Percentage of participants requiring rescue therapy during the 24-week open label
treatment period;

- To assess safety and tolerability of insulin glargine/lixisenatide FRC.